NCT00976599 - A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CP-690,550 + methotrexate

CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week

DRUG

Placebo + Methotrexate

Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week

Trial Locations (15)

21702

Pfizer Investigational Site, Frederick

35205

Pfizer Investigational Site, Birmingham

35209

Pfizer Investigational Site, Birmingham

35216

Pfizer Investigational Site, Birmingham

44060

Pfizer Investigational Site, Mentor

44094

Pfizer Investigational Site, Willoughby

44143

Pfizer Investigational Site, Mayfield Village

49015

Pfizer Investigational Site, Battle Creek

75150

Pfizer Investigational Site, Mesquite

75182

Pfizer Investigational Site, Sunnyvale

75231

Pfizer Investigational Site, Dallas

75251

Pfizer Investigational Site, Dallas

92037

Pfizer Investigational Site, La Jolla

98104

Pfizer Investigational Site, Seattle

98122

Pfizer Investigational Site, Seattle